Procter & Gamble Health Limited
NSE: PGHL · Pharmaceuticals
Snapshot
Unlock Procter & Gamble Health Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Procter & Gamble Health Limited is a pharmaceutical company that manufactures and markets vitamins, minerals, and supplements. Its portfolio includes well-known consumer health brands such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas.
Business Model
The company generates revenue through the sale of over-the-counter pharmaceutical products and health supplements in India and select international markets. It operates as a subsidiary of Procter & Gamble Overseas India B.V., leveraging established global brand equity.
- Incorporation Year:1967
Growth Outlook
Growth is driven by the sustained demand for vitamins and minerals in the Indian market and the expansion of its consumer health product footprint. The company continues to focus on its core brand portfolio to maintain market share in the pharmaceutical sector.
Key Risks
- Regulatory Risk. Changes in pharmaceutical pricing policies and drug regulations by the Indian government could impact profit margins.
- Competitive Intensity. The consumer health and supplement market is highly competitive, requiring continuous investment in brand marketing and distribution.
- Supply Chain Dependency. As a subsidiary of a multinational entity, the company is susceptible to global supply chain disruptions and fluctuations in raw material costs.
Start your research today
Unlock AI insights, financials, peers and live data on Procter & Gamble Health Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,433 Cr
TTM · standalone
NET PROFIT
₹357 Cr
TTM · standalone
EPS
₹214.99
TTM · standalone
RETURN ON EQUITY
67.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
84.2%
TTM · standalone
P/E
27.1×
Q1 FY27 · standalone
EV/EBITDA
19.7x
Q1 FY27 · standalone
EBITDA MARGIN
33.7%
TTM · standalone
NET PROFIT MARGIN
26.4%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Procter & Gamble Health LimitedPGHL | ₹9,674 Cr | 27.1× | 19.66 | 44.9% | 33.7% | 67.2% | 84.2% | -5.5% |
Strides Pharma Science LimitedSTAR | ₹9,557 Cr | 15.5× | 10.43 | 11.3% | 20.7% | 20.6% | 22.9% | +10.9% |
Blue Jet Healthcare Ltd.BLUEJET | ₹9,353 Cr | 36.5× | 26.79 | -27.5% | 39.2% | 18.8% | 25.0% | -24.7% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | ₹8,107 Cr | 29.0× | 19.51 | 22.7% | 39.9% | 92.5% | 113.0% | -27.3% |
Aarti Pharmalabs LimitedAARTIPHARM | ₹8,060 Cr | 31.4× | 17.95 | 13.4% | 22.9% | 11.9% | 14.6% | +4.3% |
Symbiotec Pharmalab LimitedSYMBIOTEC | ₹7,871 Cr | — | — | — | 27.0% | — | — | — |
As of Q1 FY27
Financials
Procter & Gamble Health Limited
NSE: PGHL · Pharmaceuticals
Snapshot
Unlock Procter & Gamble Health Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Procter & Gamble Health Limited is a pharmaceutical company that manufactures and markets vitamins, minerals, and supplements. Its portfolio includes well-known consumer health brands such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas.
Business Model
The company generates revenue through the sale of over-the-counter pharmaceutical products and health supplements in India and select international markets. It operates as a subsidiary of Procter & Gamble Overseas India B.V., leveraging established global brand equity.
- Incorporation Year:1967
Growth Outlook
Growth is driven by the sustained demand for vitamins and minerals in the Indian market and the expansion of its consumer health product footprint. The company continues to focus on its core brand portfolio to maintain market share in the pharmaceutical sector.
Key Risks
- Regulatory Risk. Changes in pharmaceutical pricing policies and drug regulations by the Indian government could impact profit margins.
- Competitive Intensity. The consumer health and supplement market is highly competitive, requiring continuous investment in brand marketing and distribution.
- Supply Chain Dependency. As a subsidiary of a multinational entity, the company is susceptible to global supply chain disruptions and fluctuations in raw material costs.
Start your research today
Unlock AI insights, financials, peers and live data on Procter & Gamble Health Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,433 Cr
TTM · standalone
NET PROFIT
₹357 Cr
TTM · standalone
EPS
₹214.99
TTM · standalone
RETURN ON EQUITY
67.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
84.2%
TTM · standalone
P/E
27.1x
Q1 FY27 · standalone
EV/EBITDA
19.7x
Q1 FY27 · standalone
EBITDA MARGIN
33.7%
TTM · standalone
NET PROFIT MARGIN
26.4%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27